These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

78 related articles for article (PubMed ID: 8729590)

  • 21. First clinical experience with low molecular weight heparin LU 47311 (reviparin) for prevention of restenosis after percutaneous transluminal coronary angioplasty.
    Schmid KM; Preisack M; Voelker W; Sujatta M; Karsch KR
    Semin Thromb Hemost; 1993; 19 Suppl 1():155-9. PubMed ID: 8395719
    [TBL] [Abstract][Full Text] [Related]  

  • 22. A meta-analysis of randomized trials of fish oil in prevention of restenosis following coronary angioplasty.
    O'Connor GT; Malenka DJ; Olmstead EM; Johnson PS; Hennekens CH
    Am J Prev Med; 1992; 8(3):186-92. PubMed ID: 1385968
    [TBL] [Abstract][Full Text] [Related]  

  • 23. An economic evaluation of fluvastatin used for the prevention of cardiac events following successful first percutaneous coronary intervention in the UK.
    Scuffham PA; Chaplin S
    Pharmacoeconomics; 2004; 22(8):525-35. PubMed ID: 15217308
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Does the new angiotensin converting enzyme inhibitor cilazapril prevent restenosis after percutaneous transluminal coronary angioplasty? Results of the MERCATOR study: a multicenter, randomized, double-blind placebo-controlled trial. Multicenter European Research Trial with Cilazapril after Angioplasty to Prevent Transluminal Coronary Obstruction and Restenosis (MERCATOR) Study Group.
    Circulation; 1992 Jul; 86(1):100-10. PubMed ID: 1535568
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Preventing restenosis with fish oils following coronary angioplasty. A meta-analysis.
    Gapinski JP; VanRuiswyk JV; Heudebert GR; Schectman GS
    Arch Intern Med; 1993 Jul; 153(13):1595-601. PubMed ID: 8323422
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Background and methods for the lovastatin restenosis trial after percutaneous transluminal coronary angioplasty. The Lovastatin Restenosis Trial Study Group.
    Weintraub WS; Boccuzzi SJ; Brown CL; Cohen CL; Hirsch LJ; King SB; Alexander RW
    Am J Cardiol; 1992 Aug; 70(3):293-9. PubMed ID: 1632391
    [TBL] [Abstract][Full Text] [Related]  

  • 27. A cost-effectiveness analysis of fluvastatin in patients with diabetes after successful percutaneous coronary intervention.
    Scuffham PA; Chaplin S
    Clin Ther; 2005 Sep; 27(9):1467-77. PubMed ID: 16291420
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Measurement errors in standard visual analysis of coronary angiograms: consequences on clinical trials.
    Bairati I; Roy L; Meyer F
    Can J Cardiol; 1993 Apr; 9(3):225-30. PubMed ID: 8508331
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Preventing cardiac events and restenosis after percutaneous coronary intervention.
    Sopko G
    JAMA; 2002 Jun; 287(24):3259-61. PubMed ID: 12076224
    [No Abstract]   [Full Text] [Related]  

  • 30. The Lescol Intervention Prevention Study (LIPS): start all patients on statins early after PCI.
    Messerli AW; Aronow HD; Sprecher DL
    Cleve Clin J Med; 2003 Jun; 70(6):561-6. PubMed ID: 12828227
    [TBL] [Abstract][Full Text] [Related]  

  • 31. The effect of pravastatin on prevention of restenosis after successful percutaneous transluminal coronary angioplasty.
    Onaka H; Hirota Y; Kita Y; Tsuji R; Ishii K; Ishimura T; Kawamura K
    Jpn Circ J; 1994 Feb; 58(2):100-6. PubMed ID: 8196151
    [TBL] [Abstract][Full Text] [Related]  

  • 32. [Anti-atherogenic drugs].
    Kanaki T; Saito Y
    Nihon Rinsho; 1998 Oct; 56(10):2635-9. PubMed ID: 9796331
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Do fish oils prevent restenosis after coronary angioplasty?
    Leaf A; Jorgensen MB; Jacobs AK; Cote G; Schoenfeld DA; Scheer J; Weiner BH; Slack JD; Kellett MA; Raizner AE
    Circulation; 1994 Nov; 90(5):2248-57. PubMed ID: 7955181
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Can aggressive efforts directed at lipid lowering post-PTCA reduce the risk of restenosis?
    Drown DJ
    Prog Cardiovasc Nurs; 1995; 10(2):40. PubMed ID: 7651950
    [No Abstract]   [Full Text] [Related]  

  • 35. Fighting restenosis after coronary angioplasty: contemporary and future treatment options.
    Horlitz M; Sigwart U; Niebauer J
    Int J Cardiol; 2002 Jun; 83(3):199-205. PubMed ID: 12036521
    [TBL] [Abstract][Full Text] [Related]  

  • 36. [Clinical trials of restenosis after PTCA and QOL of patients after PTCA].
    Okamoto S; Nakano T
    Nihon Rinsho; 1994 Jul; 52 Suppl(Pt 1):869-73. PubMed ID: 12436630
    [No Abstract]   [Full Text] [Related]  

  • 37. Evaluation of recombinant hirudin (CGP 39,393/TMREVASC) in the prevention of restenosis after percutaneous transluminal coronary angioplasty. Rationale and design of the HELVETICA trial, a multicentre randomized double blind heparin controlled study.
    Herrman JP; Simon R; Umans VA; Peerboom PF; Keane D; Rijnierse JJ; Bach D; Kobi P; Kerry R; Close P
    Eur Heart J; 1995 Nov; 16 Suppl L():56-62. PubMed ID: 8869020
    [TBL] [Abstract][Full Text] [Related]  

  • 38. [Prevention of restenosis after PTCA--a statistical problem].
    Lechleitner P
    Dtsch Med Wochenschr; 1991 May; 116(22):877. PubMed ID: 2036952
    [No Abstract]   [Full Text] [Related]  

  • 39. Randomized trial of a selective inhibitor of thromboxane A2 synthetase, (E)-7-phenyl-7-(3-pyridyl)-6-heptenoic acid (CV-4151), for prevention of restenosis after coronary angioplasty.
    Hattori R; Kodama K; Takatsu F; Yui Y; Kawai C
    Jpn Circ J; 1991 Apr; 55(4):324-9. PubMed ID: 2046138
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Restenosis revisited: insights provided by quantitative coronary angiography.
    Serruys PW; Foley DP; Kirkeeide RL; King SB
    Am Heart J; 1993 Nov; 126(5):1243-67. PubMed ID: 8237780
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 4.